Mineralys Therapeutics, Inc. (MLYS) vs Trevi Therapeutics, Inc. (TRVI)

A side-by-side comparison of Mineralys Therapeutics, Inc. and Trevi Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Mineralys Therapeutics, Inc. logo
MLYS
Mineralys Therapeutics, Inc.
$1.94B
$21.95HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Trevi Therapeutics, Inc. logo
TRVI
Trevi Therapeutics, Inc.
$1.87B
$13.18HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — MLYS vs TRVI

growth of $100 · dividends reinvested · last 4y
MLYS +26.4% (+6.0%/yr)TRVI +460.0% (+53.8%/yr)TRVI compounded faster over this window
0200400600800Start $100202420252026$126$560
MLYS TRVI

MLYS vs TRVI: by the numbers

  • •MLYS is the larger company ($1.94B vs $1.87B market cap).

Metrics side by side

Valuation

MetricMLYSTRVI
P/B ratio3.515.82

Profitability

MetricMLYSTRVI
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-63.45%-15.90%
ROIC-57.17%-18.51%

Growth (annualized)

MetricMLYSTRVI
Total return CAGR (5Y)N/A61.74%

Go deeper

Full MLYS analysisFull TRVI analysisInteractive comparison tool

Dig into the metrics

Mineralys Therapeutics ROETrevi Therapeutics ROEMineralys Therapeutics operating marginTrevi Therapeutics operating marginMineralys Therapeutics revenue growthTrevi Therapeutics revenue growthMineralys Therapeutics free cash flowTrevi Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.